ArticleFrontiers in public health2023
Multicenter study on the prevalence of colonization due to carbapenem-resistant
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Beyond Colonization: Dynamic Risk Stratification and Clinical Decision-Making for MDR Gram-Negative Infections in Critically Ill Patients.Biomedicines · 2026Review
- Antimicrobial Resistance Trends in Carbapenem-Resistant Enterobacterales in a Saudi Healthcare Setting.Microorganisms · 2026Article
- Incidence of colonization and infection with carbapenemase-producing Enterobacterales in Toronto and Peel Region, Ontario, 2007-2024.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026Article
- Clinical and cost benefit of rapid molecular screening for carbapenem-resistant organisms: a seven-year analysis in a tertiary hospital.Antimicrobial resistance and infection control · 2026Article
- When Hours Matter: A 24/7 Laboratory and Fast-Track Diagnostic Pathway for Blood Cultures in Critical Patients.Antibiotics (Basel, Switzerland) · 2026Article
- MDR Bacteremia in the Critically Ill During COVID-19: The MARTINI Study.Pathogens (Basel, Switzerland) · 2025Observational
- Beyond the Spotlight:Antibiotics (Basel, Switzerland) · 2025Review
- Characterization and transmission dynamics of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae isolated from eight teaching hospitals in Guangdong province, China (2022-2024).BMC microbiology · 2025Article
- The Impact of COVID-19 on the Epidemiology of Carbapenem Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Unveiling the impact: COVID-19's influence on bacterial resistance in the Kingdom of Bahrain.World journal of virology · 2025Article
- Circulation of a UniqueAntibiotics (Basel, Switzerland) · 2025Article
- In vitro Evaluation of the Antibacterial Activity of the Combination of Avibactam and β-Lactams Against Highly Virulent Carbapenem-ResistantInfection and drug resistance · 2025Article
- Multidrug-ResistantMicroorganisms · 2024Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Active Surveillance of Patients Colonized with CRE: A Single-Center Study Based on a Combined Molecular/Culture Protocol.Antibiotics (Basel, Switzerland) · 2024Article
- The molecular detection of carbapenem markers with a two-levels amplification screening protocol: epidemiological and resistome insights.Frontiers in microbiology · 2024Article
- The Prevalence of Multidrug-Resistant and Extensively Drug-Resistant Infections in Respiratory Intensive Care Unit, Causative Microorganisms and Mortality.Infection and drug resistance · 2024Article
- The Impact of Infection Control Policies on Hospital Acquired Infections by MDROs from 2016 to 2023.Infection and drug resistance · 2024Article
- Risk factors of Carbapenem-resistant Enterobacterales intestinal colonization for subsequent infections in hematological patients: a retrospective case-control study.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Among multidrug-resistant (MDR) bacteria able to threaten human health, carbapenem-resistant Objective: The purpose of this study was to outline the epidemiology of CRE colonization in Italy, detecting CRE-colonized patients at admission and during hospitalization, before and during the first year of COVID-19. Materials and methods: A total of 11,063 patients admitted to seven different hospitals (Bologna, Catania, Florence, Genoa, Naples, Palermo, and Turin) in Intensive Care Units (ICU) and other wards (non-ICU) located in the North, Center, and South of Italy were enrolled and screened for CRE carriage at admission (T0) and during the first 3 weeks of hospitalization (T1-T3). The study spanned two periods, before (September 2018-Septemeber 2019, I observational period) and during the COVID-19 pandemic (October 2019-September 2020, II observational period). Results: Overall, the prevalence of CRE-colonized patients at admission in ICU or in other ward, ranged from 3.9 to 11.5%, while a percentage from 5.1 to 15.5% of patients acquired CRE during hospital stay. There were large differences between the I and II period of study according to the different geographical areas and enrolling centers. Overall, comparison of prevalence of CRE-positive patients showed a significant increased trend between I and II observational periods both in ICU and non-ICU wards, mostly in the Southern participating centers. KPC-producing Conclusion: The prevalence of CRE in Italy highly increased during the COVID-19 pandemic, mostly in the Southern hospital centers. KPC-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.